Aptamer-Mediated Targeted Delivery of Therapeutics: An Update

The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer–nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.

[1]  P. Holliger,et al.  Towards applications of synthetic genetic polymers in diagnosis and therapy. , 2014, Current opinion in chemical biology.

[2]  W. Gmeiner,et al.  Dimeric DNA Aptamer Complexes for High-capacity–targeted Drug Delivery Using pH-sensitive Covalent Linkages , 2013, Molecular therapy. Nucleic acids.

[3]  furong dai,et al.  Anticancer role of MUC1 aptamer–miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation , 2012, Targeted Oncology.

[4]  Liliang Chen,et al.  Photothermal therapeutic response of cancer cells to aptamer-gold nanoparticle-hybridized graphene oxide under NIR illumination. , 2015, ACS applied materials & interfaces.

[5]  Yi Lu,et al.  The Effects of Spacer Length and Composition on Aptamer‐Mediated Cell‐Specific Targeting with Nanoscale PEGylated Liposomal Doxorubicin , 2016, Chembiochem : a European journal of chemical biology.

[6]  T. Odom,et al.  Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[7]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[8]  Ho-Keun Kwon,et al.  Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[9]  X. Qu,et al.  Near‐Infrared Light‐Triggered, Targeted Drug Delivery to Cancer Cells by Aptamer Gated Nanovehicles , 2012, Advanced materials.

[10]  T. Thongtem,et al.  Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma. , 2014, International journal of pharmaceutics.

[11]  Robert Langer,et al.  Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .

[12]  Ke Chen,et al.  Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery , 2015, Expert opinion on drug delivery.

[13]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[14]  T. Minko,et al.  Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Xiaoyuan Chen,et al.  Aptamer-Drug Conjugates. , 2015, Bioconjugate chemistry.

[16]  Guilin Wang,et al.  Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. , 2008, Expert opinion on drug delivery.

[17]  J. Katzenellenbogen,et al.  Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. , 2013, Journal of materials chemistry. B.

[18]  Chun Xing Li,et al.  An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. , 2013, Small.

[19]  B. Sullenger,et al.  Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. , 2003, Cancer research.

[20]  S. Cai,et al.  Dual targeting luminescent gold nanoclusters for tumor imaging and deep tissue therapy. , 2016, Biomaterials.

[21]  J. Behravan,et al.  Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer , 2010, Journal of drug targeting.

[22]  Mitra Dutta,et al.  Biomedical Applications of Quantum Dots, Nucleic Acid-Based Aptamers, and Nanostructures in Biosensors. , 2015, Critical reviews in biomedical engineering.

[23]  Y. Zu,et al.  A unique aptamer-drug conjugate for targeted therapy of multiple myeloma , 2016, Leukemia.

[24]  Silvia Catuogno,et al.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  L. Qiu,et al.  Targeted delivery of anticancer drugs by aptamer AS1411 mediated Pluronic F127/cyclodextrin-linked polymer composite micelles. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[26]  Soonhag Kim,et al.  Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. , 2012, Biomaterials.

[27]  Abhishek Parashar,et al.  Aptamers in Therapeutics. , 2016, Journal of clinical and diagnostic research : JCDR.

[28]  W. Gmeiner,et al.  Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. , 2016, Nanomedicine.

[29]  K. Abnous,et al.  Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. , 2016, Colloids and surfaces. B, Biointerfaces.

[30]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[31]  R. Haag,et al.  Biofunctional nanosystems based on dendritic polymers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Dong-Eun Kim,et al.  RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Won Jong Kim,et al.  Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. , 2011, Biomaterials.

[34]  Paula J. Bates,et al.  AGRO100 inhibits activation of nuclear factor-κB (NF-κB) by forming a complex with NF-κB essential modulator (NEMO) and nucleolin , 2006, Molecular Cancer Therapeutics.

[35]  Jun Li,et al.  Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery , 2012 .

[36]  C. Watson,et al.  STAT3 the oncogene – still eluding therapy? , 2015, The FEBS journal.

[37]  Ping Wu,et al.  Aptamer-functionalized graphene oxide for highly efficient loading and cancer cell-specific delivery of antitumor drug. , 2014, Journal of materials chemistry. B.

[38]  J. Lieberman,et al.  Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells , 2015, Molecular Cancer Therapeutics.

[39]  E. Gilboa,et al.  Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery , 2015, Cancer Immunology Research.

[40]  C. Esposito,et al.  Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells , 2014, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[41]  Hua Yu,et al.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. , 2014, The Journal of clinical investigation.

[42]  E. Kang,et al.  Designer tridentate mucin 1 aptamer for targeted drug delivery. , 2012, Journal of pharmaceutical sciences.

[43]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[44]  Jun-Jie Zhu,et al.  DNA-hybrid-gated multifunctional mesoporous silica nanocarriers for dual-targeted and microRNA-responsive controlled drug delivery. , 2014, Angewandte Chemie.

[45]  Xiaoling Zhang,et al.  Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.

[46]  P. Giangrande,et al.  Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL , 2016, Molecular therapy. Nucleic acids.

[47]  J. Rossi,et al.  Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky Bridge , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  S. M. Taghdisi,et al.  Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[50]  H. Sung,et al.  A FRET-guided, NIR-responsive bubble-generating liposomal system for in vivo targeted therapy with spatially and temporally precise controlled release. , 2016, Biomaterials.

[51]  Uda Hashim,et al.  Aptamer-based 'point-of-care testing'. , 2016, Biotechnology advances.

[52]  Weihong Tan,et al.  A liposome-based nanostructure for aptamer directed delivery. , 2010, Chemical communications.

[53]  Jun-Jie Zhu,et al.  Aptamer/Graphene Quantum Dots Nanocomposite Capped Fluorescent Mesoporous Silica Nanoparticles for Intracellular Drug Delivery and Real-Time Monitoring of Drug Release. , 2015, Analytical chemistry.

[54]  Tao Wang,et al.  EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model , 2015, Theranostics.

[55]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[56]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[57]  Omid C Farokhzad,et al.  Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo , 2011, Proceedings of the National Academy of Sciences.

[58]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[59]  M. Yeh,et al.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.

[60]  Ronghua Yang,et al.  Regulation of singlet oxygen generation using single-walled carbon nanotubes. , 2008, Journal of the American Chemical Society.

[61]  Yong-mei Song,et al.  Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro , 2012, Journal of Translational Medicine.

[62]  S. M. Taghdisi,et al.  Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles. , 2016, Materials science & engineering. C, Materials for biological applications.

[63]  Shu-Jyuan Yang,et al.  Aptamer-based tumor-targeted drug delivery for photodynamic therapy. , 2010, ACS nano.

[64]  E. Gilboa,et al.  Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay , 2010, Nature.

[65]  M. Seong,et al.  Gold nanoparticle-DNA aptamer composites as a universal carrier for in vivo delivery of biologically functional proteins. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[66]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[67]  P. Wu,et al.  Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery. , 2014, ACS applied materials & interfaces.

[68]  EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex , 2015, Journal of Biomedical Science.

[69]  Q. Ma,et al.  A novel aptamer functionalized CuInS2 quantum dots probe for daunorubicin sensing and near infrared imaging of prostate cancer cells. , 2014, Analytica chimica acta.

[70]  Yi-Fang Cheng,et al.  A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. , 2013, The Journal of allergy and clinical immunology.

[71]  Hsin-Yun Hsu,et al.  Non-metallic nanomaterials in cancer theranostics: a review of silica- and carbon-based drug delivery systems , 2013, Science and technology of advanced materials.

[72]  G. Pauletti,et al.  Solubilization of flurbiprofen into aptamer-modified PEG–PLA micelles for targeted delivery to brain-derived endothelial cells in vitro , 2013, Journal of microencapsulation.

[73]  Chao Liang,et al.  Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers , 2016, International journal of molecular sciences.

[74]  Wei Zheng,et al.  Targeted delivery of doxorubicin to breast cancer cells by aptamer functionalized DOTAP/DOPE liposomes. , 2015, Oncology reports.

[75]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[76]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[77]  Xiaoke Zhang,et al.  Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. , 2012, Biomaterials.

[78]  Yun-Ling Luo,et al.  Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. , 2011, ACS nano.

[79]  B. Sullenger,et al.  Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. , 2012, Nucleic acid therapeutics.

[80]  Xi‐lin Xiao,et al.  A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy , 2015, PloS one.

[81]  Weihong Tan,et al.  DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells , 2009, Proceedings of the National Academy of Sciences.

[82]  R. Kanwar,et al.  Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer , 2012, Molecular vision.

[83]  Xiaoqi Sun,et al.  Near-infrared light-activated cancer cell targeting and drug delivery with aptamer-modified nanostructures , 2015, Nano Research.

[84]  Dunqiang Ren,et al.  Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells , 2015, PloS one.

[85]  Rassoul Dinarvand,et al.  Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. , 2016, Colloids and surfaces. B, Biointerfaces.

[86]  M. Elimelech,et al.  Toxic effects of single-walled carbon nanotubes in the development of E. coli biofilm. , 2010, Environmental science & technology.

[87]  Meral Yüce,et al.  Trends in aptamer selection methods and applications. , 2015, The Analyst.

[88]  L. Marchetti,et al.  Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells , 2015, Molecular therapy. Nucleic acids.

[89]  Z. Liao,et al.  An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[90]  Xiangling Xiong,et al.  Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. , 2012, Chemistry, an Asian journal.

[91]  Wei-Yun Lai,et al.  Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. , 2014, Biomaterials.

[92]  Yitao Wang,et al.  Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel , 2015, Nano Research.

[93]  Xiaojuan He,et al.  Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems , 2015, International journal of molecular sciences.

[94]  Keith E. Maier,et al.  From selection hits to clinical leads: progress in aptamer discovery , 2016, Molecular therapy. Methods & clinical development.

[95]  Walhan Alshaer,et al.  Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. , 2015, Bioconjugate chemistry.

[96]  Dhananjay Dendukuri,et al.  Synthesis and self-assembly of amphiphilic polymeric microparticles. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[97]  J. Burnett,et al.  Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells , 2013, Nucleic acids research.

[98]  C. Esposito,et al.  Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[99]  L. Ricci-Vitiani,et al.  A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[100]  Wei Duan,et al.  Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[101]  Jian Wang,et al.  Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. , 2012, ACS nano.

[102]  Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA. , 2016, Methods in molecular biology.

[103]  M. Aghasadeghi,et al.  Smart bomb AS1411 aptamer‐functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer , 2017, Clinical and experimental pharmacology & physiology.

[104]  A. Ellington,et al.  Directed evolution of gold nanoparticle delivery to cells. , 2010, Chemical communications.

[105]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[106]  H. Mukhtar,et al.  Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. , 2013, Biomaterials.

[107]  S. Thayumanavan,et al.  Supramolecular assemblies of amphiphilic homopolymers. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[108]  Xin Lu,et al.  Novel MUC1 Aptamer Selectively Delivers Cytotoxic Agent to Cancer Cells In Vitro , 2012, PloS one.

[109]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[110]  S. M. Taghdisi,et al.  Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[111]  J. Rossi,et al.  An Aptamer-siRNA Chimera Suppresses HIV-1 Viral Loads and Protects from Helper CD4+ T Cell Decline in Humanized Mice , 2011, Science Translational Medicine.

[112]  J. Burnett,et al.  Aptamer-siRNA chimeras for HIV. , 2015, Advances in experimental medicine and biology.

[113]  M. Ramezani,et al.  AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro. , 2016, Journal of pharmaceutical sciences.

[114]  W. Tan,et al.  Targeted Delivery of Chemotherapy Agents Using a Liver Cancer-Specific Aptamer , 2012, PloS one.

[115]  W. Gradishar,et al.  Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.

[116]  Ariel D. Anbar,et al.  Aptamers Evolved from Cultured Cancer Cells Reveal Molecular Differences of Cancer Cells in Patient Samples , 2007 .

[117]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[118]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[119]  S. M. Taghdisi,et al.  Targeted and controlled release delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer-modified gold nanoparticles. , 2015, International journal of pharmaceutics.

[120]  John J. Rossi,et al.  Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy , 2014, Molecular therapy. Nucleic acids.

[121]  Yi Lu,et al.  Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.

[122]  J. She,et al.  Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer , 2016, Scientific Reports.

[123]  S. Barth,et al.  Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. , 2008, Current cancer drug targets.

[124]  Mark W. Ball,et al.  AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. , 2006, Molecular cancer therapeutics.

[125]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  A. Kouzani,et al.  Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine , 2015, Theranostics.

[127]  Boeun Lee,et al.  Inhibition of discoidin domain receptor 2-mediated lung cancer cells progression by gold nanoparticle-aptamer-assisted delivery of peptides containing transmembrane-juxtamembrane 1/2 domain. , 2015, Biochemical and biophysical research communications.

[128]  K. Ye,et al.  A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery , 2016, International journal of molecular sciences.